Qualio

I'm looking to add two talented salespeople to the Qualio team. We're hiring for both an Account Executive and an Enterprise Account Executive. If you know someone who'd be a great fit, or if that someone is you, let's talk! Check out our job postings: https://lnkd.in/gAbKRNTs

Most biotech compliance functions aren't short on people. They're short on capacity. The difference matters. When evidence lives across disconnected systems, your most experienced quality professionals spend weeks before every inspection doing work the architecture should have already handled. Reconciling records. Assembling documentation chains. Verifying that what's in one platform matches what's in another. That's not a staffing gap. It's an infrastructure design problem. And it has a ceiling. Every new program, manufacturing site, or regulatory jurisdiction multiplies the number of connections that need to be managed. Headcount absorbs the cost. It doesn't change what the work consists of. The organizations managing compliance well as they scale aren't running unusually large quality teams. They've built architectures that keep compliance effort stable as complexity grows. Compliance runs in parallel with product development, not as a bottleneck ahead of it. If the next headcount request on your desk is driven by reconciliation, coordination, and evidence assembly across disconnected systems: that's worth examining before approving. We wrote about the structural shift that changes the equation: https://hubs.ly/Q04hl9T30

70% of FDA PMA submissions are rejected on first review. Not because the device wasn't ready. Because the submission wasn't. Class III medical device companies spend years on clinical trials, safety data, and engineering evidence, then stumble on the paperwork. Here's why it happens: The PMA process is not just rigorous. It is structured in a specific sequence. Miss a step. Misclassify a section. Submit incomplete clinical data. And you're not just delayed — you're starting over. The teams that get it right the first time aren't smarter. They have a roadmap. We built one. Qualio's Complete FDA PMA Submission Guide walks you through the entire process — from classifying your device and choosing a submission type, to the exact ingredients a successful PMA requires. Includes: → End-to-end PMA roadmap → Common mistakes to avoid (and why they cause rejections) → Insights from real quality and regulatory professionals → Everything you need for a right-first-time submission Instant access. No email required. Get your guide: https://hubs.ly/Q04h8W0C0

Most biotech companies don't fail at IND because they were unprepared. They fail because they thought they were ready. A clean GLP audit feels like validation. It signals control. It suggests the system is working. But IND doesn't test whether your system worked in preclinical. It tests whether your system can handle what comes next. Filing triggers 21 CFR Part 312. ICH E6 GCP layers in. CDMO oversight becomes a real accountability structure. A new VP of Quality inherits a system built for a much simpler world. At that moment, a gap appears. We call it the Heroics Gap: the extra manual effort required to stretch a research-focused system into clinical-stage compliance. It doesn't eliminate risk. It postpones when that risk becomes visible. Here are 6 signs your quality system is running on heroics, not infrastructure: 1. Audit prep is measured in weeks, not days 2. CDMO oversight lives in spreadsheets and email, not your quality system 3. SOPs get updated before inspections, not continuously 4. CRO change control runs through email threads 5. Your risk register is a standalone document, not connected to clinical reality 6. Too much of your system lives in one person's head None of these show up in preclinical. IND is where they compound, simultaneously. If you're within 6 to 9 months of IND, the window to close these gaps on your terms is now. Not during. Not after. Full breakdown here: https://hubs.ly/Q04h1k2T0

Most biotech companies don't fail because of bad science. They miss timelines because of how they've built their compliance infrastructure. Not the people. Not the intent. The architecture. The pattern is familiar: weeks before a regulatory interaction, teams begin reconstructing evidence. Batch records reconciled. Deviations cross-referenced. Documentation reviewed. Data integrity checks intensified. It gets labeled "audit prep." It's actually a symptom of an operating model that becomes more expensive at every milestone. The enforcement data makes the stakes concrete. The FDA issued 327 warning letters in the second half of 2025 alone — a 73% increase over the same period in 2024. More than a third cited GMP violations. Often for small documentation failures that a continuous compliance architecture would have caught months earlier. The question for biotech leaders isn't whether compliance matters. It's whether the architecture in place can support what comes next. We wrote about this, and what the companies that get it right actually do differently. 🔗https://hubs.ly/Q04gQDYr0

Passing your last audit doesn't mean you're ready to scale. Medical device companies under FDA and EU MDR pressure are discovering a frustrating pattern: audits pass, but submissions still slip. Engineering gets pulled into quality firefighting at the worst moments. Leadership loses confidence right before critical milestones. We call it the Readiness Paradox. In our new white paper, we explore why audit success has stopped predicting operational readiness, where traditional QMS approaches break down as companies grow, and how leading MedTech teams are building continuous readiness into their quality systems to protect product velocity. If your team is scaling, this one is worth the read. Get the white paper: https://hubs.ly/Q04g7Nfh0

Regulatory pressure isn't easing up. But the way compliance teams respond to it is changing...fast. Join us on June 18th at 9:00 AM CST for Qualio Accelerate 2026, our live virtual event for life sciences leaders who want to stay ahead of what's next in quality, compliance, and AI. This year, we're exploring how AI and agentic systems are fundamentally rewriting the rules of compliance, helping teams move from reactive firefighting to proactive, intelligent operations. Here's what you'll walk away with: ✅ Strategies to reduce audit risk ✅ Proven approaches to accelerate product timelines ✅ Ways to scale compliance operations with confidence ✅ A clear view of what the next era of life sciences innovation demands from your quality function You'll hear directly from industry experts and the Qualio team — practical, actionable insights you can put to work immediately. If you're leading quality or compliance at a life sciences company, this is the event you don't want to miss. 🔗 Register now to save your spot: https://hubs.ly/Q04gB4Dj0

Most growth-stage biotech companies are audit-ready. Far fewer are scale-ready. Those aren't the same thing. Audit-ready means your system can demonstrate compliance when asked. Scale-ready means it maintains compliance as the business grows, without requiring proportional increases in manual effort. The gap between the two has a name: episodic readiness. It works well in a small, stable environment. It has a ceiling. And that ceiling is almost always reached at the worst possible moment: IND submission, early Phase I, a financing round with investors doing operational diligence. By then, the cost of fixing it is higher than the cost of preventing it. We wrote about this operating model distinction in detail. Worth reading if you're in the 12 months around IND. https://hubs.ly/Q04g76Vt0

I wrote Qualio's CDSCO registration guide in May 2024. A lot has happened since. India’s medical device regulator has been more active in the past 18 months than at any point since the Medical Devices Rules 2017 took effect. Since then, we’ve seen: • Three FAQ addenda • A draft guidance on medical device software • New post-approval change procedures • BIS Scheme X compliance milestones • Portal improvements that actually save time As a manufacturer, it may be worth verifying whether your India submission strategy is still based on the 2024 framework, and whether it reflects the regulatory updates introduced since then. One of the more significant updates is the October 2025 SaMD guidance, which distinguishes between Software in a Medical Device and Software as a Medical Device, each with its own classification logic, documentation requirements, and licensing pathway. Another important point for existing license holders: endorsements added to an import license follow the validity of the base license, rather than operating on a separate timeline. I’ve updated Qualio’s CDSCO registration guide to cover what’s changed, what’s stayed the same, and what’s stayed the same, and key regulatory developments manufacturers may want to review, including BIS Scheme X where applicable. If you’re preparing a CDSCO dossier, managing existing Indian licenses, or advising companies entering the Indian market. Please find the full guide below: https://lnkd.in/e-5FNftj

India just became a lot more complicated to ignore. CDSCO has quietly overhauled key parts of its medical device framework over the past 18 months. If your India market entry plan was built on guidance from 2024, it needs a review. Here's what changed: Software as a Medical Device now has its own classification framework. For the first time, SaMD and SiMD are formally distinguished, with separate documentation requirements, licensing pathways, and post-market surveillance obligations. If you're building digital health tools, AI diagnostics, or any standalone clinical software, India's regulatory bar just got higher and clearer. Three FAQ addenda have been issued since mid-2024, closing real-world gaps around labeling, re-import approvals, post-approval changes, and what happens when you change your authorized Indian representative (spoiler: you need a fresh license). The BIS Scheme X certification deadline is September 1, 2026. That's not a future problem. That's now. The Sugam portal can now auto-generate Market Standing and Non-Conviction Certificates digitally. Small change, significant time savings. The sterilization loan license requirement has been removed for manufacturers using already-licensed facilities. What hasn't changed: the four risk classes, the MD-14/15 and MD-5/6 form structure, the 5-year retention fee cycle, and the ISO 13485 requirement. Our updated guide, written by SUMATHA KONDABOLU (22 years in QA/RA across med devices and pharma), covers all of it. https://hubs.ly/Q04fTVSL0